RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA
Clinical trials for RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Smarter CMV strategy may protect stem cell transplant patients
Disease control OngoingThis study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…
Matched conditions: RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 07:56 UTC
-
New combo targets hard-to-treat leukemia in early trial
Disease control OngoingThis study tests a new drug combination (venetoclax plus vincristine) in 40 adults with T-cell or B-cell acute lymphoblastic leukemia that has returned or not responded to prior therapy. The goal is to find the safest dose and see if the combination helps achieve remission. Parti…
Matched conditions: RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 26, 2026 07:50 UTC
-
Engineered T-Cells show promise in lymphoma fight
Disease control OngoingThis early-phase trial tests the safety and best dose of specially modified T-cells (immune cells) given after a stem cell transplant for people with high-risk or returning non-Hodgkin lymphoma. The modified T-cells are designed to recognize and attack cancer cells. The study inv…
Matched conditions: RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 18, 2026 12:03 UTC